title: Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?
abstract: OBJECTIVE
  Recent studies have demonstrated the relevance of (18)F-FDG uptake as an independent prognostic factor for recurrence of operable non-small cell lung cancer (NSCLC). This corresponds with the experimental finding that FDG uptake correlates with the proliferative activity of tumour cells (Higashi et al., J Nucl Med 2000;41:85-92). On the basis of these observations, we studied the influence of FDG uptake on prognosis and occurrence of distant metastases in patients with advanced NSCLC.
  
  
  METHODS
  One hundred and fifty-nine patients with NSCLC of UICC stage IIIA or IIIB were included in the study. In all patients, neoadjuvant treatment was planned to achieve operability. FDG PET was performed as an additional staging procedure prior to the initiation of therapy. Clinical outcome data in terms of overall survival, disease-free survival and incidence of distant metastases could be obtained for 137 patients and were correlated with the average standardised uptake value of the tumour (SUV(avg)). Furthermore, other factors influencing SUV(avg) and patient outcome (histological tumour type, grading, UICC stage, tumour size) were analysed.
  
  
  RESULTS
  SUV(avg) was significantly influenced by tumour histology, UICC stage and tumour size. No significant difference could be shown for grading. In 38 out of the 159 patients (24%), FDG PET revealed previously unsuspected distant metastases. The incidence of distant metastases significantly correlated with SUV(avg). Overall survival tended to decrease with increasing SUV(avg); however, significance was only reached when a cut-off of 12.0 was applied (p=0.05).
  
  
  CONCLUSIONS
  FDG uptake is an independent prognostic factor in patients with UICC stage III NSCLC, although less distinctively so than has been reported for stage I/II tumours.
authors.affiliation: Department of Nuclear Medicine, University of Tübingen, Otfried-Mueller-Strasse 14, 72076 Tübingen, Germany. susanne-martina.eschmann@med.uni-tuebingen.de
authors.forename: S M
authors.initials: SM
authors.lastname: Eschmann
authors.forename: G
authors.initials: G
authors.lastname: Friedel
authors.forename: F
authors.initials: F
authors.lastname: Paulsen
authors.forename: M
authors.initials: M
authors.lastname: Reimold
authors.forename: T
authors.initials: T
authors.lastname: Hehr
authors.forename: W
authors.initials: W
authors.lastname: Budach
authors.forename: J
authors.initials: J
authors.lastname: Scheiderbauer
authors.forename: H J
authors.initials: HJ
authors.lastname: Machulla
authors.forename: H
authors.initials: H
authors.lastname: Dittmann
authors.forename: R
authors.initials: R
authors.lastname: Vonthein
authors.forename: R
authors.initials: R
authors.lastname: Bares
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000401:mortality*; D018572:Disease-Free Survival; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006801:Humans; D007090:Image Interpretation, Computer-Assisted / Q000379:methods / Q000592:standards*; D015994:Incidence; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000401:mortality*; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D011379:Prognosis; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012016:Reference Values; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D015996:Survival Rate
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18